Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377] Draft guidance Technology appraisal guidance 10 January 2025 Cladribine for ...

Cost-effectiveness thresholds play a vital role in healthcare decision-making, helping to ensure that NHS resources are used ...

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer TA1021 4 December 2024 4 December 2024 ...

26 May 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-June 2023.

We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type ...

Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments TA1023 11 December 2024 11 December 2024 ...

For further information on the guideline development process, please see how we develop NICE guidelines ...

Tirzepatide's gastrointestinal adverse effects could lead to dehydration and in turn a deterioration in renal function including acute renal failure. Older people and some other groups of people may ...

Anhydrous sodium thiosulfate, also known as Pedmarqsi and made by Norgine, is recommended in final draft guidance for preventing hearing loss caused by cisplatin chemotherapy in children from the ages ...

Following the Technology Appraisal Committee meeting on 13 August 2024, we are consulting with consultees and commentators on the case for extending the statutory 3-month period for funding of ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.